Analystreport

Milestone Pharmaceuticals (NASDAQ:MIST) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.

Milestone Pharmaceuticals Inc. - Common Shares  (MIST) 
Last milestone pharmaceuticals inc. - common shares earnings: 3/6 07:00 am Check Earnings Report